United States Healthcare Equipment & Supplies

T2 Biosystems Inc (TTOO)

Track

Ticker: TTOO Exchange: NMS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for T2 Biosystems Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Sale 13 Sep 2024
Value US$1,839,746.06 | Price 427.54 | Shares 19,923 (-5.7%)
Proposed sale 13 Sep 2024
Value US$3,652,694.21 | Price 297.68 | Shares 65,332
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2024-09-17 2024-09-13 S Sale
Elsbree David B
Non-Executive Director
19,923 -5.7%
427.54
US$1,839,746 		19,923 -5.7% 427.54 US$1,839,746
2024-09-13 2024-09-13 PrS Proposed sale
Elsbree David B

Director

Non-Executive Director
65,332
297.68
US$3,652,694 		65,332 297.68 US$3,652,694
2023-09-29 2023-09-28 S Sale
3.6
CR Group L.P.
Large shareholder
40,021 +6.0%
171.80
US$3,716,223 		40,021 +6.0% 171.80 US$3,716,223
2023-09-29 2023-09-28 S Sale
3.6
CR Group L.P.
Large shareholder
571,796 -100.0%
0.16
US$90,058 		571,796 -100.0% 0.16 US$90,058
2023-09-29 2023-09-28 S Sale
3.6
CR Group L.P.
Large shareholder
1,780,317 -100.0%
0.16
US$280,400 		1,780,317 -100.0% 0.16 US$280,400
2023-09-29 2023-09-28 S Sale
3.6
CR Group L.P.
Large shareholder
2,858,980 -100.0%
0.16
US$450,289 		2,858,980 -100.0% 0.16 US$450,289
2023-09-29 2023-09-27 S Sale
3.6
CR Group L.P.
Large shareholder
1,621,313 -45.6%
0.19
US$310,644 		1,621,313 -45.6% 0.19 US$310,644
2023-09-29 2023-09-27 S Sale
3.6
CR Group L.P.
Large shareholder
478,396 -45.6%
0.19
US$91,661 		478,396 -45.6% 0.19 US$91,661
2023-09-29 2023-09-27 S Sale
3.6
CR Group L.P.
Large shareholder
1,489,512 -45.6%
0.19
US$285,390 		1,489,512 -45.6% 0.19 US$285,390
2023-09-29 2023-09-27 S Sale
3.6
CR Group L.P.
Large shareholder
2,391,981 -45.6%
0.19
US$458,304 		2,391,981 -45.6% 0.19 US$458,304
2023-09-28 2023-09-26 S Sale
3.6
CR Group L.P.
Large shareholder
1,461,849 -29.1%
0.20
US$293,393 		1,461,849 -29.1% 0.20 US$293,393
2023-09-28 2023-09-26 S Sale
3.6
CR Group L.P.
Large shareholder
431,343 -29.1%
0.20
US$86,571 		431,343 -29.1% 0.20 US$86,571
2023-09-28 2023-09-26 S Sale
3.6
CR Group L.P.
Large shareholder
1,343,011 -29.1%
0.20
US$269,542 		1,343,011 -29.1% 0.20 US$269,542
2023-09-28 2023-09-26 S Sale
3.6
CR Group L.P.
Large shareholder
2,156,717 -29.1%
0.20
US$432,853 		2,156,717 -29.1% 0.20 US$432,853
2023-09-27 2023-09-25 S Sale
3.6
CR Group L.P.
Large shareholder
67,767 -1.3%
0.25
US$16,942 		67,767 -1.3% 0.25 US$16,942
2023-09-27 2023-09-25 S Sale
3.6
CR Group L.P.
Large shareholder
19,996 -1.3%
0.25
US$4,999 		19,996 -1.3% 0.25 US$4,999
2023-09-27 2023-09-25 S Sale
3.6
CR Group L.P.
Large shareholder
62,258 -1.3%
0.25
US$15,564 		62,258 -1.3% 0.25 US$15,564
2023-09-27 2023-09-25 S Sale
3.6
CR Group L.P.
Large shareholder
99,979 -1.3%
0.25
US$24,995 		99,979 -1.3% 0.25 US$24,995
2023-09-26 2023-09-22 S Sale
3.6
CR Group L.P.
Large shareholder
1,376,848 -21.3%
0.26
US$356,328 		1,376,848 -21.3% 0.26 US$356,328
2023-09-26 2023-09-22 S Sale
3.6
CR Group L.P.
Large shareholder
406,263 -21.3%
0.26
US$105,141 		406,263 -21.3% 0.26 US$105,141
2023-09-26 2023-09-22 S Sale
3.6
CR Group L.P.
Large shareholder
1,264,920 -21.3%
0.26
US$327,361 		1,264,920 -21.3% 0.26 US$327,361
2023-09-26 2023-09-22 S Sale
3.6
CR Group L.P.
Large shareholder
2,031,313 -21.3%
0.26
US$525,704 		2,031,313 -21.3% 0.26 US$525,704
2023-09-25 2023-09-21 S Sale
3.6
CR Group L.P.
Large shareholder
1,718,087 -21.0%
0.30
US$516,285 		1,718,087 -21.0% 0.30 US$516,285
2023-09-25 2023-09-21 S Sale
3.6
CR Group L.P.
Large shareholder
506,951 -21.0%
0.30
US$152,339 		506,951 -21.0% 0.30 US$152,339
2023-09-25 2023-09-21 S Sale
3.6
CR Group L.P.
Large shareholder
1,578,419 -21.0%
0.30
US$474,315 		1,578,419 -21.0% 0.30 US$474,315
2023-09-25 2023-09-21 S Sale
3.6
CR Group L.P.
Large shareholder
2,534,754 -21.0%
0.30
US$761,694 		2,534,754 -21.0% 0.30 US$761,694
2023-09-22 2023-09-20 S Sale
3.6
CR Group L.P.
Large shareholder
2,101,784 -20.4%
0.31
US$652,814 		2,101,784 -20.4% 0.31 US$652,814
2023-09-22 2023-09-20 S Sale
3.6
CR Group L.P.
Large shareholder
620,167 -20.4%
0.31
US$192,624 		620,167 -20.4% 0.31 US$192,624
2023-09-22 2023-09-20 S Sale
3.6
CR Group L.P.
Large shareholder
1,930,923 -20.4%
0.31
US$599,745 		1,930,923 -20.4% 0.31 US$599,745
2023-09-22 2023-09-20 S Sale
3.6
CR Group L.P.
Large shareholder
3,100,836 -20.4%
0.31
US$963,120 		3,100,836 -20.4% 0.31 US$963,120
2023-09-21 2023-09-19 S Sale
3.6
CR Group L.P.
Large shareholder
2,819,506 -21.5%
0.37
US$1,031,939 		2,819,506 -21.5% 0.37 US$1,031,939
2023-09-21 2023-09-19 S Sale
3.6
CR Group L.P.
Large shareholder
831,943 -21.5%
0.37
US$304,491 		831,943 -21.5% 0.37 US$304,491
2023-09-21 2023-09-19 S Sale
3.6
CR Group L.P.
Large shareholder
2,590,300 -21.5%
0.37
US$948,050 		2,590,300 -21.5% 0.37 US$948,050
2023-09-21 2023-09-19 S Sale
3.6
CR Group L.P.
Large shareholder
4,159,717 -21.5%
0.37
US$1,522,456 		4,159,717 -21.5% 0.37 US$1,522,456
2023-04-06 2023-03-28 PlS Planned sale
2.1
Gibbs Michael Terrence

General Counsel

Officer
239 -3.5%
0.48
US$115 		239 -3.5% 0.48 US$115
2023-03-09 2023-02-28 PlS Planned sale
2.1
Gibbs Michael Terrence

General Counsel

Officer
1,585 -19.6%
0.59
US$935 		1,585 -19.6% 0.59 US$935
2023-03-09 2023-02-28 PlS Planned sale
0.5
Sperzel John J III

Chairman and CEO

Executive Director
2,898 -14.3%
0.59
US$1,710 		2,898 -14.3% 0.59 US$1,710
2023-03-09 2023-02-28 PlS Planned sale
1.4
Sprague John M

Chief Financial Officer

Officer
1,148 -13.6%
0.59
US$677 		1,148 -13.6% 0.59 US$677
2023-03-09 2023-02-22 PlS Planned sale
2.1
Gibbs Michael Terrence

General Counsel

Officer
2,145 -29.3%
0.65
US$1,394 		2,145 -29.3% 0.65 US$1,394
2023-03-09 2023-02-22 PlS Planned sale
0.5
Sperzel John J III

Chairman and CEO

Executive Director
6,875 -33.6%
0.65
US$4,469 		6,875 -33.6% 0.65 US$4,469
2023-03-09 2023-02-22 PlS Planned sale
1.0
Giffin Brett A.

Chief Commercial Officer

Officer
537 -39.0%
0.65
US$349 		537 -39.0% 0.65 US$349
2023-03-09 2023-02-22 PlS Planned sale
1.4
Sprague John M

Chief Financial Officer

Officer
1,545 -21.9%
0.65
US$1,004 		1,545 -21.9% 0.65 US$1,004
2022-11-22 2022-11-10 S Sale
1.0
Giffin Brett A.

Chief Commercial Officer

Officer
1,292 -36.4%
1.79
US$2,317 		1,292 -36.4% 1.79 US$2,317
2022-04-11 2022-04-08 B Purchase
0.5
Barclay Alec

Chief Operations Officer

Officer
12,952 +7.7%
0.50
US$6,476 		12,952 +7.7% 0.50 US$6,476
2022-04-11 2022-04-08 B Purchase
1.4
Sprague John M

Chief Financial Officer

Officer
10,000 +7.0%
0.48
US$4,767 		10,000 +7.0% 0.48 US$4,767
2022-04-11 2022-04-08 B Purchase
1.0
Giffin Brett A.

Chief Commercial Officer

Officer
10,600 +inf%
0.49
US$5,183 		10,600 +inf% 0.49 US$5,183
2022-04-11 2022-04-07 B Purchase
2.1
Gibbs Michael Terrence

General Counsel

Officer
10,000 +6.4%
0.49
US$4,900 		10,000 +6.4% 0.49 US$4,900
2022-04-11 2022-04-07 B Purchase
0.5
Sperzel John J III

Chairman, CEO, and President

Executive Director
30,000 +15.6%
0.50
US$15,000 		30,000 +15.6% 0.50 US$15,000
2022-01-10 2022-01-06 PlS Planned sale
Ahuja Aparna

Chief Medical Officer

Officer
61,988 -36.5%
0.48
US$29,754 		61,988 -36.5% 0.48 US$29,754
2021-03-25 2021-03-25 PlS Planned sale
2.1
Gibbs Michael Terrence

General Counsel

Officer
8,758 -10.7%
1.56
US$13,662 		8,758 -10.7% 1.56 US$13,662
2021-03-18 2021-03-17 PlS Planned sale
0.5
Barclay Alec

Chief Operations Officer

Officer
12,494 -14.4%
1.86
US$23,239 		12,494 -14.4% 1.86 US$23,239
2021-03-18 2021-03-17 PlS Planned sale
Pare Anthony

Chief Commercial Officer

Officer
9,620 -23.3%
1.84
US$17,701 		9,620 -23.3% 1.84 US$17,701
2021-02-23 2021-02-23 PlS Planned sale
1.4
Sprague John M

Chief Financial Officer

Officer
5,250 -12.9%
2.04
US$10,710 		5,250 -12.9% 2.04 US$10,710
2021-02-23 2021-02-23 PlS Planned sale
2.1
Gibbs Michael Terrence

General Counsel

Officer
7,280 -10.0%
2.06
US$14,997 		7,280 -10.0% 2.06 US$14,997
2021-02-23 2021-02-23 PlS Planned sale
0.5
Barclay Alec

Chief Operations Officer

Officer
7,280 -10.0%
2.06
US$14,997 		7,280 -10.0% 2.06 US$14,997
2020-03-03 2020-02-24 S Sale
1.4
Sprague John M

Chief Financial Officer

Officer
4,166 -15.8%
0.82
US$3,416 		4,166 -15.8% 0.82 US$3,416
2020-02-25 2020-02-24 PlS Planned sale
2.6
Lowery Thomas J.

Chief Scientific Officer

Officer
5,808 -7.8%
0.82
US$4,763 		5,808 -7.8% 0.82 US$4,763
2020-02-25 2020-02-24 PlS Planned sale
2.1
Gibbs Michael Terrence

General Counsel

Officer
5,808 -8.7%
0.82
US$4,763 		5,808 -8.7% 0.82 US$4,763
2020-02-25 2020-02-24 PlS Planned sale
0.5
Barclay Alec

SVP, Operations

Officer
5,808 -11.1%
0.82
US$4,763 		5,808 -11.1% 0.82 US$4,763
2020-02-12 2020-02-11 PlS Planned sale
2.6
Lowery Thomas J.

Chief Scientific Officer

Officer
3,200 -4.7%
0.77
US$2,464 		3,200 -4.7% 0.77 US$2,464
2020-02-12 2020-02-11 PlS Planned sale
2.1
Gibbs Michael Terrence

General Counsel

Officer
3,200 -5.4%
0.77
US$2,464 		3,200 -5.4% 0.77 US$2,464
2020-02-05 2020-02-03 PlS Planned sale
2.1
Gibbs Michael Terrence

General Counsel
3,283 -5.7%
0.88
US$2,889 		3,283 -5.7% 0.88 US$2,889
2020-02-05 2020-02-03 PlS Planned sale
2.6
McDonough John
23,754 -4.6%
0.88
US$20,904 		23,754 -4.6% 0.88 US$20,904
2020-02-05 2020-02-03 PlS Planned sale
2.6
Lowery Thomas J.

Chief Scientific Officer
7,535 -10.8%
0.88
US$6,631 		7,535 -10.8% 0.88 US$6,631
2020-01-27 2020-01-23 PlS Planned sale
2.6
McDonough John
57,417 -10.1%
1.15
US$66,030 		57,417 -10.1% 1.15 US$66,030
2020-01-07 2020-01-03 PlS Planned sale
Elsbree David B
5,316 -5.5%
1.16
US$6,167 		5,316 -5.5% 1.16 US$6,167
2019-09-13 2019-09-11 PlS Planned sale
0.5
Barclay Alec

SVP, Operations
4,210 -9.1%
2.92
US$12,293 		4,210 -9.1% 2.92 US$12,293
2019-06-13 2019-06-11 PlS Planned sale
Cima Michael J.
3,240 -1.5%
1.43
US$4,633 		3,240 -1.5% 1.43 US$4,633
2019-06-13 2019-06-11 PlS Planned sale
CUMMING JOHN W
3,420 -12.7%
1.43
US$4,891 		3,420 -12.7% 1.43 US$4,891
2019-06-13 2019-06-11 PlS Planned sale
2.9
Lapidus Stanley
9,000 -14.5%
1.44
US$12,960 		9,000 -14.5% 1.44 US$12,960
2019-06-13 2019-06-11 PlS Planned sale
Elsbree David B
3,600 -4.2%
1.44
US$5,184 		3,600 -4.2% 1.44 US$5,184
2019-02-12 2019-02-11 PlS Planned sale
2.1
Gibbs Michael Terrence

General Counsel

Officer
3,005 -5.0%
3.36
US$10,097 		3,005 -5.0% 3.36 US$10,097
2019-02-12 2019-02-11 PlS Planned sale
2.6
McDonough John

President & CEO

Executive Director
8,134 -1.8%
3.36
US$27,330 		8,134 -1.8% 3.36 US$27,330
2019-02-12 2019-02-11 PlS Planned sale
2.6
Lowery Thomas J.

Chief Scientific Officer

Officer
3,005 -4.1%
3.36
US$10,097 		3,005 -4.1% 3.36 US$10,097
2019-02-05 2019-02-01 S Sale
2.1
Gibbs Michael Terrence

General Counsel

Officer
1,820 -3.2%
3.47
US$6,315 		1,820 -3.2% 3.47 US$6,315
Explore more

More insider trading research around T2 Biosystems Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Healthcare Services companies with insider activity
More Healthcare Equipment & Supplies companies with insider activity
Insider trading in North America